lemme glp-1 dailytm capsules Daily (NOT SPONSORED) by a dietitian Lemme GLP-1 Daily: Supresa-Based GLP-1

In addition to glycemic control and weight loss, certain GLP-1 receptor agonists have FDA-approved indications to lower the risk for major adverse cardiovascular events, address moderate to severe obstructive sleep apnea, and, most recently, reduce the risk for worsening kidney disease, kidney failure, and cardiovascular death

And then the PCN number is M E DD G L P 1BR

Monitoring and Review Clinicians should arrange appropriate monitoring and review for people with T2D who are treated with GLP-1 RAs

Services should be registered with the Care Quality Commission (CQC), use a General Pharmaceutical Council (GPhC)-registered pharmacy, and employ UK-registered prescribers (GMC, NMC, or GPhC)